LGD-4033 vs Trazodone
Moderate Research vs FDA Approved
monitor Mechanism-based · 51% Both LGD-4033 and Trazodone can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
LGD-4033 Trazodone
Weight 338.25 Da 371.86 Da
Half-life ~24-36 hours ~5-9 hours
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) Triazolopyridine derivative (C19H22ClN5O)
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Trazodone
01 Effective sleep aid that improves sleep onset and sleep maintenance without the dependence risk of benzodiazepines
02 Enhances slow-wave (deep) sleep, which is critical for physical recovery and growth hormone release
03 Non-habit-forming with no significant tolerance development, even with long-term use
04 Widely used and well-tolerated solution for trenbolone-induced and steroid-related insomnia
05 Does not suppress REM sleep the way many other sleep medications do
06 Inexpensive, widely available as a generic, and has decades of safety data
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Trazodone
Morning drowsiness or grogginess (dose-dependent, more common above 50 mg)
Dry mouth
Dizziness or lightheadedness, particularly upon standing (orthostatic hypotension)
Headache
Nausea (reduced by taking with food)
Blurred vision
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Known hypersensitivity to trazodone
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
History of priapism or conditions predisposing to priapism (e.g., sickle cell disease, multiple myeloma, leukemia)
Severe hepatic impairment (dose adjustment required in moderate impairment)
Recent myocardial infarction or unstable cardiac conditions
Pregnancy, particularly first trimester (Category C; limited human data)
Research Evidence
LGD-4033 Trazodone
Status Moderate Research FDA Approved
References 5 studies 4 studies
Latest 2018 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.